Diabetes mellitus (DM) is a serious metabolic disorder that afflicts more than 370 million people worldwide. Of these, 90% have Type 2 (T2DM), which results in life-threatening complications including chronic kidney failure and cardiovascular disease. In fact, 65% of Type 2 diabetics die prematurely of heart disease or stroke (1).
With the goal of improving diabetes care, scientists are actively searching for novel biomarkers that can predict the onset of disease and inform clinicians about the efficacy of both lifestyle changes and drug interventions. A wide range of candidate markers are under investigation, including gut and pituitary hormones, acute phase proteins, adipokines, cytokines, proteinases, nutrient binding proteins, and growth factors. When studied together, these markers can help researchers elucidate the complex relationship between metabolic and cardiovascular diseases, and ultimately enable more effective and personalized disease treatment. Both Pharma and academic researchers can benefit greatly from the ability to analyze multiple disease-associated biomarkers in each patient sample.
In this Webinar, you will learn:
- How diabetes and related metabolic conditions are linked to cardiovascular disease
- Which protein biomarkers are currently being studied in these conditions
- The importance of rigorous assay validation for reliable multiplex biomarker detection
- How to leverage the Bio-Plex™ Pro RBM Human Metabolic and Hormone assays to profile multiple protein biomarkers relevant to metabolic and cardiovascular diseases
Register today!
(1) Data from American Heart Association Website
James P. Mapes, Ph.D.,
Chief Scientific Officer, Myriad RBM
Dr. Mapes has more than 25 years experience in the development and commercialization of diagnostic and research assay kits. Before joining Myriad RBM, Dr. Mapes was Director of Research and Development for Luminex Corporation. Prior to Luminex, he worked for Becton Dickinson as Director of Clinical Affairs, where he was responsible for biological and clinical evaluation of new products. Previously, he was with Bayer Diagnostics, EnSys Corporation and Becton Dickinson with increasing responsibilities in research and development management. After post-doctoral training at Oxford University, Oxford, England, and Texas A&M University, he held a faculty position in the Biochemistry Department at Louisiana State University Medical Center in New Orleans. Dr. Mapes received his Ph.D. in Biochemistry at Indiana University.
- How diabetes and related metabolic conditions are linked to cardiovascular disease
- Which protein biomarkers are currently being studied in these conditions
- The importance of rigorous assay validation for reliable multiplex biomarker detection
- How to leverage the Bio-Plex™ Pro RBM Human Metabolic assays to profile multiple protein biomarkers relevant to metabolic and cardiovascular diseases
- Life Science Researchers in:
- Diabetes
- Obesity
- Metabolic Diseases
- Cardiovascular Disease
- Autoimmune Disease
- Cancer
- Immunology
- Inflammation
- Oxidant Defense
- VP
